Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
U3-1287 + trastuzumab + paclitaxel
- Development stage
- Unknown
- Lead developer
- Daiichi Sankyo
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
U3-1287 + trastuzumab + paclitaxel is an experimental combination therapy for advanced solid tumors and HER2-positive breast cancer. U3-1287 (patritumab, also known as AMG 888) is a fully human monoclonal antibody targeting HER3, aiming to inhibit oncogenic signaling mediated by the HER3 receptor, which plays a critical role in resistance to HER family inhibitors. Trastuzumab is a monoclonal antibody against HER2, used for HER2-overexpressing breast cancer, functioning by blocking HER2-mediated cell growth. Paclitaxel is a microtubule-stabilizing small molecule chemotherapeutic that disrupts mitosis. Together, this combination targets HER2 and HER3 receptors, aiming for synergistic anti-tumor activity by dual inhibition of oncogenic pathways and cytotoxicity. U3-1287 is primarily developed by Daiichi Sankyo/U3 Pharma, trastuzumab by Genentech (Roche), and paclitaxel is produced by various companies.
- Other names
- patritumab + trastuzumab + paclitaxel
02
Targets
TUBB (Tubulin (alpha and beta subunits))ERBB3 (Erb-b2 receptor tyrosine kinase 3)ERBB2 (Erb-b2 receptor tyrosine kinase 2)
Beyond the preview
Go deeper on U3-1287 + trastuzumab + paclitaxel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on U3-1287 + trastuzumab + paclitaxel.